PODIUM TALK

Novel Health Strategies team presented 23 studies at ISPOR 2018 Annual Meeting in Baltimore on market access strategy, pricing and health economic and outcomes research trends.

These studies were led by Novel Health team and are good examples of wide breadth and depth of our expertise.

NOVEL was also selected for a PODIUM session and nominated for TWO AWARDS.

In-person replays of all presentations are available upon request.

PCN66 BURDEN OF HOSPITALIZATION IN LUNG CANCER PATIENTS WITH BRAIN METASTASES: ANALYSIS OF US NATIONAL IN-PATIENT DATA FOR 2015 USING ICD-9 AND ICD-10 DIAGNOSES

PCN110 COST EFFECTIVENESS OF ANTI-PD-1/PD-L1 TREATMENTS: SYSTEMATIC REVIEW OF PUBLISHED STUDIES

PCN65 HOSPITAL LENGHT OF STAY AND COSTS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: ANALYSIS OF US NATIONAL IN-PATIENT DATA FOR 2015

PIN49 HOSPITAL LENGHT OF STAY AND COSTS IN PATIENTS WITH POST OPERATIVE WOUND INFECTION: ANALYSIS OF US NATIONAL IN-PATIENT DATA FOR 2015 USING ICD-9 AND ICD-10 DIAGNOSES

PUK14 HOSPITAL LENGHT OF STAY AND COSTS IN PATIENTS WITH URINARY TRACK INFECTIONS: ANALYSIS OF US NATIONAL IN-PATIENT DATA FOR 2015 USING ICD-9 AND ICD-10 DIAGNOSES

PCN142 HOSPITALIZATION LENGHT OF STAY AND COSTS IN PATIENTS WITH MULTIPLE MYELOMA: ANALYSIS OF US NATIONAL IN-PATIENT DATA FOR 2015

PMS5 REAL WORLD EVIDENCE FOR EFFECTIVENESS OF BIOLOGICS FOR RHEUMATOID ARTHRITIS: SYSTEMATIC LITERATURE REVIEW OF POPULATION BASED REGISTRY STUDIES

PIH17 TRENDS IN HOSPITALIZATION LENGHT OF STAY AND COSTS IN ENDOMETRIOSIS: ANALYSIS OF US NATIONAL IN-PATIENT DATA FOR 2015

PND36 TRENDS IN HOSPITALIZATION LENGHT OF STAY AND COSTS IN PATIENTS WITH ABNORMAL INVOLUNTARY MOVEMENT DISORDERS: ANALYSIS OF US NATIONAL IN-PATIENT DATA FOR 2015

PRS18 TRENDS IN HOSPITALIZATION LENGHT OF STAY AND COSTS IN PATIENTS WITH ALPHA 1 ANTITRYPSIN DEFICIENCY DISORDER: ANALYSIS OF US NATIONAL IN-PATIENT DATA FOR 2015

PCN69 TRENDS IN HOSPITALIZATION LENGHT OF STAY AND COSTS IN PATIENTS WITH CHRONIC LYMPHOID LEUKEMIA: ANALYSIS OF US NATIONAL IN-PATIENT DATA FOR 2015

PGI10 TRENDS IN HOSPITALIZATION LENGHT OF STAY AND COSTS IN PATIENTS WITH CROHN'S DISEASE: ANALYSIS OF US NATIONAL IN-PATIENT DATA FOR 2015

PCN141 TRENDS IN HOSPITALIZATION LENGHT OF STAY AND COSTS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): ANALYSIS OF US NATIONAL IN-PATIENT DATA FOR 2015

PSY60 TRENDS IN HOSPITALIZATION LENGHT OF STAY AND COSTS IN PATIENTS WITH HEREDITARY ANGIOEDEMA: ANALYSIS OF US NATIONAL IN-PATIENT DATA FOR 2015

PCN143 TRENDS IN HOSPITALIZATION LENGHT OF STAY AND COSTS IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA (PTCL): ANALYSIS OF US NATIONAL IN-PATIENT DATA FOR 2015

PSY61 TRENDS IN HOSPITALIZATION LENGHT OF STAY AND COSTS IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY: ANALYSIS OF US NATIONAL IN-PATIENT DATA FOR 2015

PIN50 TRENDS IN HOSPITALIZATION LENGHT OF STAY, SEASONALITY AND COSTS IN PATIENTS WITH INFLUENZA INFECTION: ANALYSIS OF US NATIONAL IN-PATIENT DATA FOR 2015 USING ICD-9 AND ICD-10 DIAGNOSES

PIN48 TRENDS IN HOSPITALIZATION LENGHT OF STAY, SEASONALITY AND COSTS IN PATIENTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION: ANALYSIS OF US NATIONAL IN-PATIENT DATA FOR 2015 USING ICD-9 AND ICD-10 DIAGNOSES

PHP77 IMPACT OF PRIOR AUTHORIZATION ON MARKET ACCESS AND PATIENT OUTCOMES: INSIGHTS FROM SYSTEMATIC LITERATURE REVIEW (2013-2017)

PHP78 ROLE OF PATIENT ASSISTANCE PROGRAM (PAP) IN MARKET ACCESS AND OUTCOMES: INSIGHTS FROM SYSTEMATIC LITERATURE REVIEW (2013-2017)

PSY126 TRENDS IN HTA SUBMISSIONS FOR RARE DISEASES: INSIGHTS FROM REVIEW OF NICE'S HIGHLY SPECIALIZED TECHNOLOGY (HST) ASSESSMENT REPORTS

HT3 USING REAL-WORLD EVIDENCE FOR HEALTH TECHNOLOGY ASSESSMENT SUBMISSIONS: LESSONS AND INSIGHTS FROM REVIEW OF NICE'S TECHNOLOGY ASSESSMENT REPORTS (2016-2017)****

**** Also selected a podium presentation (For comparison: ICON plc with 13,360 employees was selected for 1 podium presentation, NOVEL was also selected for a podium presentation)